Eloxx Pharmaceuticals Inc (ELOX)

ELOX moved to NASDAQ from the OTC

https://otce.finra.org/otce/dailyList?viewType=Deletions

ELOX: effective June 1,2026 a one for 11 reverse split

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

$ELOX "As of December 31, 2025, we owned or licensed 66 issued patents and 101 pending patent applications in the U.S. and abroad, not including U.S. provisional applications." - page 7 of https://www.otcmarkets.com/filing/html?id=19254028&guid=elC-kWIA7b1joVh

$ELOX team members have very strong backgrounds - https://www.eloxxpharma.com/about-us/

$ELOX if the price per share is not high enough, the approved reverse split is a good way for ELOX's planned uplisting back to the Nasdaq (it was delisted 10/16/2023) - "to effect a reverse stock split ... on or prior to the one-year anniversary of the Record Date; and ... to decrease the number of authorized shares of Common Stock from 500,000,000 to 100,000,000." - https://www.otcmarkets.com/filing/html?id=19426768&guid=elC-kWIA7b1joVh

$ELOX "We have also exclusively licensed ZKN-013 ... to Almirall. ... we received an upfront payment of $3 million and a development milestone of $3 million in 2024. Almirall is responsible for development and commercialization of ZKN-013 and we are eligible to receive up to approximately $470.0 million in additional development, regulatory and commercial milestone payments as well as tiered royalties based on global sales." - page 90 of https://www.otcmarkets.com/filing/html?id=19422811&guid=EUC-knncHerOV3h

$ELOX "Exaluren has received Orphan Drug Designation for the treatment of AS from the FDA. ... We have evaluated exaluren in eight clinical trials ... In these studies, no dose-limiting toxicities were reported and no serious adverse events were attributed to exaluren." - page 89 of https://www.otcmarkets.com/filing/html?id=19422811&guid=EUC-knncHerOV3h

$ELOX "In August 2025, we entered into a securities purchase agreement with Coastlands Capital Partners LP (“Coastlands”), pursuant to which Coastlands invested $15.0 million and Domicilium invested $2.0 million and converted all of our outstanding indebtedness. With renewed access to capital, we completed the audits of our consolidated financial statements for the fiscal years ended December 31, 2023, 2024 and 2025 and filed an Annual Report on Form 10-K for those same years, which is required for our planned uplisting to the Nasdaq Capital Market." - page 4 of https://www.otcmarkets.com/filing/html?id=19422811&guid=EUC-knncHerOV3h

Wow! ELOX, will do 20 for 1 R/S: "approved amendments to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-2 to 1-for-20, with the exact ratio to be determined at the sole discretion of the Company’s Board of Directors (the “Board”) at any time on or prior to the one-year anniversary of the Record Date; and"

https://www.otcmarkets.com/filing/html?id=19426768&guid=Oaj-kaxcBwI2dth

$ELOX: from the 03/17/2026-filed 10-K (page F-37 and page F-38, respectively):
1. "on February 26, 2026, the Coastlands Third Tranche Closing occurred and the Company received $5.0 million in return for a pre-funded warrant to purchase up to 10,204,081 shares of its common stock at an exercise price of $0.01 per share, based on a purchase price of $0.49 per share of underlying common stock."
2. "As of February 26, 2026, the Company had no remaining outstanding debt obligations. On March 12, 2026, the Company received $2.0 million from Domicilium, in return for a pre-funded warrant to purchase up to 4,081,632 shares of its common stock as an exercise price of $0.01 per share, based on a purchase price of $0.49 per share of underlying common stock."

$ELOX:
1. last week upgraded from Expert Market to Pink Limited;
2. was delisted from Nasdaq in 2023;
3. great technology to treat cancer and inflammatory diseases;
4. recently updated website;
5. strong team.

It's scary out there in stock swampland.

This one and BLPH which was also delisted today…
Times 250 trading sessions in a calendar year works out to 500 third tier NASDAQ companies
One could say “no way”
In my view even high risk taking hedge funds are no longer interested

Effective Oct 16,2023 ELOX delisted from the Nasdaq to the OTC. ***PPS closed at $3.82 before the delisting notice.

https://otce.finra.org/otce/dailyList?viewType=Additions

SOON ....."It's high time for the next run. I've been acquiring shares at a bargain."

Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

THER STOCK..WILL JUMP SAME WAY

THER CANCER TESTS AND TREATMENT OPTIONS

THERALINK.COM

Going to be nasdaq merger with BACK

i agree. The Webull session from 4am to 7am US Eastern is, to varying degrees, a synthetic market.
The 7am to 9:30 period can be a period when insider dumping takes place.

Like to see 10.9 break during regular hours will make that chart look good on next dip ,higher highs

ELOX it’s going higher

Are you making me wet

Impressed

ELOX: Told-ya-all-so, it it's movin' AGAIN!!! (Wildest day across the Markets in History of the COSMOS!!!)

ELOX: Easiest profit day-trade in the history of Mankind --- hands-down WINNER of this day!!

ELOX halted

$ELOX - Up 14% Pre-Market/ Current Price $4.69
Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

?????????

?????????

oh wow, just got back from bike ride, 14.78 thats insane

16 bucks comin up

9.77 lol

should have known the way the OVER run these low floaters

but yes I agree

Better to sell into strength

ELOX 7.77 sold a little early lol

out last bit 7.17

https://finviz.com/quote.ashx?t=ELOX&ty=c&ta=1&p=d

What a move here

Sold a few
Waiting on the dip

ELOX: (BREAKING NEWS!!) Hey, GAIL --- & our Pal, Mr. Emperor EZ --- this Puppy might be ready (again) for LAUNCH this looming Monday!!! (However, I sincerely hope that I do NOT make an abject, humiliating, FOOL of myself all over again, though.)
https://www.nasdaq.com/articles/oppenheimer-reiterates-eloxx-pharmaceuticals-elox-outperform-recommendation

here we goooo

moving back up now. lets do this!

grabbed some on the dip here.

$ELOX: Now 4.60 ......... HAAAaaaaaaaaaaaaaaaaaaaa


One by one......... Right after the OTHER


This MARKET ............. YEEEEEEeeowwwwwwwwwwwwww



$TMNA is next......... I Can feel it in my LOINS


GO $ELOX

$ELOX: Only 2Milly floater........... going now at 3.30


Worth watching again.


Some bigggggggggg winners recently like MDGL and TGTX


GO $ELOX

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Source: GlobeNewswire Inc.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation. The combination trial of ELX-02 with ivacaftor was well tolerated but did not achieve statistical significance for efficacy endpoints, including changes from baseline in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1).
“We are disappointed that ELX-02 failed to achieve statistical significance for its key efficacy endpoints in this Phase 2 trial in combination with ivacaftor for the treatment of Class 1 CF. Despite this setback, we were pleased to observe that ELX-02 was well tolerated and demonstrated additional evidence of activity in this underserved patient population. We will work closely with the CF Foundation, as it has generously supported this trial, to determine the next steps in the development of ELX-02 for CF,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Mr. Aggarwal continued, “Given the safety and evidence of activity we have observed to date with ELX-02, including in this trial, we look forward to initiating a proof-of-concept trial for ELX-02 in Alport syndrome, a rare kidney disease, later this year. Given the likelihood of increased drug exposure, as ELX-02 is preferentially taken up in the kidneys, we believe ELX-02 is well suited to potentially deliver transformative results in these patients.”

Topline Results of ELX-02 Phase 2 Combination Trial in Class 1 CF Patients

The Phase 2 combination clinical trial of ELX-02 was designed to evaluate safety and assess biological activity in G542X nonsense mutation Class 1 CF patients as monotherapy and in combination with ivacaftor. The trial included a 1-week monotherapy period (1.5 mg/kg daily subcutaneous) followed by a four week combination period (1.5 mg/kg daily subcutaneous and 150 mg ivacaftor twice daily). Topline results are summarized below:

ELX-02 was generally well tolerated in the trial, with no treatment-related serious adverse events noted.
Overall, the study did not achieve statistical significance for efficacy endpoints in the Phase 2 study in Class 1 CF for efficacy endpoints, including changes from baseline in SCC and FEV1.
No incremental improvement was observed with ivacaftor combination.
Evidence of activity for ELX-02 was observed, as patients with higher baseline sweat chloride levels demonstrated increased responses as indicated by SCC (p=0.00013 at Day 35).
Trial results were potentially confounded by high variability in sweat chloride and lung function measurement.
Eloxx believes this variability could have been caused by very low drug exposures in the lung. Steady state lung drug levels in patients from this trial were on average 20%, or 2µM, of the lowest levels at which drug activity has previously been seen in preclinical testing.
Lung drug exposure with inhaled delivery of ELX-02 expected to be at least 50-fold greater than with subcutaneous delivery.
About Class 1 CF

CF patients with a Class 1 nonsense mutation remain highly underserved with no approved disease modifying therapies. An estimated 10-12% of CF patients are Class 1 patients with one or both alleles harboring nonsense mutations, leading to less than full length CFTR proteins on the cell membrane in these patients.

Conference Call and Webcast

Eloxx’s management will host a conference call and webcast today at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the “Investors” tab on the Eloxx website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is (888) 672-2415 for domestic participants and (646) 307-1963 for international participants, with Conference ID # 7410846. Please dial in at least 15 minutes in advance to ensure a timely connection to the call.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02 for the treatment of CF patients with nonsense mutations. In addition, ELX-02 has also been granted Orphan Drug Designation for the treatment of CF patients with nonsense mutations by the FDA and orphan medicinal product designation by the European Commission. ELX-02 is in clinical development, focusing on cystic fibrosis (US Trial NCT04135495, EU/IL Trial NCT04126473). Eloxx also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

For more information, please visit www.eloxxpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, the expected timing of trials of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financials-filings.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact

Investors
John Woolford
john.woolford@westwicke.com
443.213.0506

Media
Laureen Cassidy
laureen@outcomescg.com

Source: Eloxx Pharmaceuticals, Inc.



Primary Logo

Looks good for a return here

Buckle up. About to move higher. This one was unfairly beat down. Do your own due diligence, but check out some of the price targets on this one. Multiples of 3-4 x higher than current SP./ok2

Buy whatever you can afford on this one. It ran up hard today but fell back down. One day this will take off and you won't want to be chasing it. Take advantage of the cheap ones offered. Will have a year in 2022. Best of luck to the longs./ok2

Fingers crossed!

ELOX... .7387 close... .7105 bid here after hours... GidDy uP ELOX...
https://schrts.co/mwRgYFGI

Massive runup today on a nod from Oppenheimer and Company. This investment house indicated that they are now following ELOX and have put a $4 PT on the stock. Hit $1.01, but didn't hold. Not grabbing for pennies, waiting for dollars in profit. Did not sell any. All the best to the longs./ok2

Not sure what I am missing. Why the 50 percent sell off